IASO Bio’s Nanjing Manufacturing Facility Granted the Drug Manufacturing License for CAR-T Cell Therapy Products

SHANGHAI and NANJING, China and SAN FRANCISCO, March 1, 2022 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products announced that the company's...

Click to view original post